Analysis of 500 bone marrow transplants from unrelated donors (UR-BMT) facilitated by the Japan Marrow Donor Program: Confirmation of UR-BMT as a standard therapy for patients with leukemia and aplastic anemia

Y. Kodera, Y. Morishima, S. Kato, Y. Akiyama, H. Sao, T. Matsuyama, K. Kawa, H. Sakamaki, S. Nakagawa, N. Hirabayashi, H. Dohi, Shinichiro Okamoto, A. Hiraoka, H. Gondo, M. Tsuchida, H. O, M. Harada, S. Asano, T. Juji, T. SasazukiF. Takaku

Research output: Contribution to journalArticle

67 Citations (Scopus)

Abstract

In December 1991, the Japan Marrow Donor Program (JMDP) was established with the cooperation of the Japanese Red Cross and Japan Marrow Donor Foundation under the auspices of the Ministry of Health and Welfare in Japan. By December 1998, 122,365 HLA-A,B typed volunteer marrow donors and 7207 patients had been cumulatively registered in the JMDP. The results of HLA-matching between donors and patients revealed that 5684 out of 7207 (78.9%) patients could have at least one HLA-A,B,DR serologically matched donor. Among these matched pairs, 1829 unrelated bone marrow transplants (UR-BMT) were performed. The initial 500 UR-BMT transplanted from January 1993 to October 1995 were analyzed as of July 1998. Engraftment was achieved in 95% of cases. Probability of the occurrence of grade III and IV acute GVHD was 18.4%. The rate of disease-free survival (DFS) of the patients who had standard-risk leukemia and did not suffer from grade III or IV acute GVHD (n = 154) was 60-71% and the rate of survival of patients with aplastic anemia was 56%. It can be stated that UR-BMT is a modality of treatment which is as effective as related BMT if the occurrence of grade III or IV acute GVHD is predicted and prevented.

Original languageEnglish
Pages (from-to)995-1003
Number of pages9
JournalBone Marrow Transplantation
Volume24
Issue number9
Publication statusPublished - 1999

Fingerprint

Unrelated Donors
Aplastic Anemia
Japan
Leukemia
Bone Marrow
Tissue Donors
Transplants
HLA-A Antigens
HLA-B Antigens
Therapeutics
Red Cross
Disease-Free Survival
Volunteers
Survival Rate
Health

Keywords

  • Acute GVHD
  • Bone marrow transplant from unrelated donor (UR-BMT)
  • Chronic GVHD
  • Japan marrow donor program (JMPD)
  • Survival

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Analysis of 500 bone marrow transplants from unrelated donors (UR-BMT) facilitated by the Japan Marrow Donor Program : Confirmation of UR-BMT as a standard therapy for patients with leukemia and aplastic anemia. / Kodera, Y.; Morishima, Y.; Kato, S.; Akiyama, Y.; Sao, H.; Matsuyama, T.; Kawa, K.; Sakamaki, H.; Nakagawa, S.; Hirabayashi, N.; Dohi, H.; Okamoto, Shinichiro; Hiraoka, A.; Gondo, H.; Tsuchida, M.; O, H.; Harada, M.; Asano, S.; Juji, T.; Sasazuki, T.; Takaku, F.

In: Bone Marrow Transplantation, Vol. 24, No. 9, 1999, p. 995-1003.

Research output: Contribution to journalArticle

Kodera, Y, Morishima, Y, Kato, S, Akiyama, Y, Sao, H, Matsuyama, T, Kawa, K, Sakamaki, H, Nakagawa, S, Hirabayashi, N, Dohi, H, Okamoto, S, Hiraoka, A, Gondo, H, Tsuchida, M, O, H, Harada, M, Asano, S, Juji, T, Sasazuki, T & Takaku, F 1999, 'Analysis of 500 bone marrow transplants from unrelated donors (UR-BMT) facilitated by the Japan Marrow Donor Program: Confirmation of UR-BMT as a standard therapy for patients with leukemia and aplastic anemia', Bone Marrow Transplantation, vol. 24, no. 9, pp. 995-1003.
Kodera, Y. ; Morishima, Y. ; Kato, S. ; Akiyama, Y. ; Sao, H. ; Matsuyama, T. ; Kawa, K. ; Sakamaki, H. ; Nakagawa, S. ; Hirabayashi, N. ; Dohi, H. ; Okamoto, Shinichiro ; Hiraoka, A. ; Gondo, H. ; Tsuchida, M. ; O, H. ; Harada, M. ; Asano, S. ; Juji, T. ; Sasazuki, T. ; Takaku, F. / Analysis of 500 bone marrow transplants from unrelated donors (UR-BMT) facilitated by the Japan Marrow Donor Program : Confirmation of UR-BMT as a standard therapy for patients with leukemia and aplastic anemia. In: Bone Marrow Transplantation. 1999 ; Vol. 24, No. 9. pp. 995-1003.
@article{446e93dc00104461b25810144e3724e8,
title = "Analysis of 500 bone marrow transplants from unrelated donors (UR-BMT) facilitated by the Japan Marrow Donor Program: Confirmation of UR-BMT as a standard therapy for patients with leukemia and aplastic anemia",
abstract = "In December 1991, the Japan Marrow Donor Program (JMDP) was established with the cooperation of the Japanese Red Cross and Japan Marrow Donor Foundation under the auspices of the Ministry of Health and Welfare in Japan. By December 1998, 122,365 HLA-A,B typed volunteer marrow donors and 7207 patients had been cumulatively registered in the JMDP. The results of HLA-matching between donors and patients revealed that 5684 out of 7207 (78.9{\%}) patients could have at least one HLA-A,B,DR serologically matched donor. Among these matched pairs, 1829 unrelated bone marrow transplants (UR-BMT) were performed. The initial 500 UR-BMT transplanted from January 1993 to October 1995 were analyzed as of July 1998. Engraftment was achieved in 95{\%} of cases. Probability of the occurrence of grade III and IV acute GVHD was 18.4{\%}. The rate of disease-free survival (DFS) of the patients who had standard-risk leukemia and did not suffer from grade III or IV acute GVHD (n = 154) was 60-71{\%} and the rate of survival of patients with aplastic anemia was 56{\%}. It can be stated that UR-BMT is a modality of treatment which is as effective as related BMT if the occurrence of grade III or IV acute GVHD is predicted and prevented.",
keywords = "Acute GVHD, Bone marrow transplant from unrelated donor (UR-BMT), Chronic GVHD, Japan marrow donor program (JMPD), Survival",
author = "Y. Kodera and Y. Morishima and S. Kato and Y. Akiyama and H. Sao and T. Matsuyama and K. Kawa and H. Sakamaki and S. Nakagawa and N. Hirabayashi and H. Dohi and Shinichiro Okamoto and A. Hiraoka and H. Gondo and M. Tsuchida and H. O and M. Harada and S. Asano and T. Juji and T. Sasazuki and F. Takaku",
year = "1999",
language = "English",
volume = "24",
pages = "995--1003",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "9",

}

TY - JOUR

T1 - Analysis of 500 bone marrow transplants from unrelated donors (UR-BMT) facilitated by the Japan Marrow Donor Program

T2 - Confirmation of UR-BMT as a standard therapy for patients with leukemia and aplastic anemia

AU - Kodera, Y.

AU - Morishima, Y.

AU - Kato, S.

AU - Akiyama, Y.

AU - Sao, H.

AU - Matsuyama, T.

AU - Kawa, K.

AU - Sakamaki, H.

AU - Nakagawa, S.

AU - Hirabayashi, N.

AU - Dohi, H.

AU - Okamoto, Shinichiro

AU - Hiraoka, A.

AU - Gondo, H.

AU - Tsuchida, M.

AU - O, H.

AU - Harada, M.

AU - Asano, S.

AU - Juji, T.

AU - Sasazuki, T.

AU - Takaku, F.

PY - 1999

Y1 - 1999

N2 - In December 1991, the Japan Marrow Donor Program (JMDP) was established with the cooperation of the Japanese Red Cross and Japan Marrow Donor Foundation under the auspices of the Ministry of Health and Welfare in Japan. By December 1998, 122,365 HLA-A,B typed volunteer marrow donors and 7207 patients had been cumulatively registered in the JMDP. The results of HLA-matching between donors and patients revealed that 5684 out of 7207 (78.9%) patients could have at least one HLA-A,B,DR serologically matched donor. Among these matched pairs, 1829 unrelated bone marrow transplants (UR-BMT) were performed. The initial 500 UR-BMT transplanted from January 1993 to October 1995 were analyzed as of July 1998. Engraftment was achieved in 95% of cases. Probability of the occurrence of grade III and IV acute GVHD was 18.4%. The rate of disease-free survival (DFS) of the patients who had standard-risk leukemia and did not suffer from grade III or IV acute GVHD (n = 154) was 60-71% and the rate of survival of patients with aplastic anemia was 56%. It can be stated that UR-BMT is a modality of treatment which is as effective as related BMT if the occurrence of grade III or IV acute GVHD is predicted and prevented.

AB - In December 1991, the Japan Marrow Donor Program (JMDP) was established with the cooperation of the Japanese Red Cross and Japan Marrow Donor Foundation under the auspices of the Ministry of Health and Welfare in Japan. By December 1998, 122,365 HLA-A,B typed volunteer marrow donors and 7207 patients had been cumulatively registered in the JMDP. The results of HLA-matching between donors and patients revealed that 5684 out of 7207 (78.9%) patients could have at least one HLA-A,B,DR serologically matched donor. Among these matched pairs, 1829 unrelated bone marrow transplants (UR-BMT) were performed. The initial 500 UR-BMT transplanted from January 1993 to October 1995 were analyzed as of July 1998. Engraftment was achieved in 95% of cases. Probability of the occurrence of grade III and IV acute GVHD was 18.4%. The rate of disease-free survival (DFS) of the patients who had standard-risk leukemia and did not suffer from grade III or IV acute GVHD (n = 154) was 60-71% and the rate of survival of patients with aplastic anemia was 56%. It can be stated that UR-BMT is a modality of treatment which is as effective as related BMT if the occurrence of grade III or IV acute GVHD is predicted and prevented.

KW - Acute GVHD

KW - Bone marrow transplant from unrelated donor (UR-BMT)

KW - Chronic GVHD

KW - Japan marrow donor program (JMPD)

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=0032694870&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032694870&partnerID=8YFLogxK

M3 - Article

C2 - 10556959

AN - SCOPUS:0032694870

VL - 24

SP - 995

EP - 1003

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 9

ER -